-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Decreases By 25.3%
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Decreases By 25.3%
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 57,500 shares, a decrease of 25.3% from the July 15th total of 77,000 shares. Currently, 1.1% of the company's shares are short sold. Based on an average daily volume of 469,900 shares, the short-interest ratio is currently 0.1 days.
Insider Transactions at Indaptus Therapeutics
In related news, CEO Jeffrey A. Meckler purchased 19,727 shares of the business's stock in a transaction dated Monday, June 6th. The shares were purchased at an average cost of $2.63 per share, for a total transaction of $51,882.01. Following the completion of the acquisition, the chief executive officer now owns 45,374 shares in the company, valued at approximately $119,333.62. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 36.00% of the company's stock.
Get Indaptus Therapeutics alerts:Institutional Trading of Indaptus Therapeutics
A number of hedge funds have recently added to or reduced their stakes in INDP. Northern Trust Corp purchased a new stake in Indaptus Therapeutics in the first quarter worth about $41,000. Renaissance Technologies LLC purchased a new stake in Indaptus Therapeutics in the second quarter worth about $51,000. State Street Corp purchased a new stake in Indaptus Therapeutics in the first quarter worth about $78,000. Investment House LLC lifted its stake in Indaptus Therapeutics by 272.8% in the fourth quarter. Investment House LLC now owns 95,629 shares of the company's stock worth $545,000 after acquiring an additional 69,976 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Indaptus Therapeutics by 18.7% in the first quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock worth $969,000 after acquiring an additional 38,216 shares during the period. 22.26% of the stock is owned by hedge funds and other institutional investors.
Indaptus Therapeutics Stock Performance
NASDAQ INDP opened at $2.99 on Friday. Indaptus Therapeutics has a 12 month low of $1.89 and a 12 month high of $28.83. The company's 50-day moving average price is $2.77 and its 200-day moving average price is $3.35.Indaptus Therapeutics (NASDAQ:INDP – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). As a group, equities research analysts expect that Indaptus Therapeutics will post -1.85 earnings per share for the current year.
Indaptus Therapeutics Company Profile
(Get Rating)
Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.
See Also
- Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Indaptus Therapeutics, Inc. (NASDAQ:INDP – Get Rating) was the recipient of a significant decrease in short interest during the month of July. As of July 31st, there was short interest totalling 57,500 shares, a decrease of 25.3% from the July 15th total of 77,000 shares. Currently, 1.1% of the company's shares are short sold. Based on an average daily volume of 469,900 shares, the short-interest ratio is currently 0.1 days.
Indaptus治療公司(納斯達克:INDP-GET評級)是7月份空頭股數使用量大幅下降的接受者。截至7月31日,空頭股數共有57,500股,比7月15日的77,000股減少了25.3%。目前,該公司1.1%的股票被賣空。以日均成交量46.99萬股計算,目前短息比為0.1天。
Insider Transactions at Indaptus Therapeutics
Indaptus治療公司的內幕交易
In related news, CEO Jeffrey A. Meckler purchased 19,727 shares of the business's stock in a transaction dated Monday, June 6th. The shares were purchased at an average cost of $2.63 per share, for a total transaction of $51,882.01. Following the completion of the acquisition, the chief executive officer now owns 45,374 shares in the company, valued at approximately $119,333.62. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 36.00% of the company's stock.
在相關新聞中,首席執行官傑弗裏·A·梅克勒在一筆日期為6月6日星期一的交易中購買了該公司19,727股股票。這些股票是以每股2.63美元的平均成本購買的,總交易額為51,882.01美元。收購完成後,首席執行官現在擁有該公司45,374股,價值約119,333.62美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過這個超級鏈接訪問。公司內部人士持有該公司36.00%的股份。
Institutional Trading of Indaptus Therapeutics
Indaptus治療藥物的機構交易
A number of hedge funds have recently added to or reduced their stakes in INDP. Northern Trust Corp purchased a new stake in Indaptus Therapeutics in the first quarter worth about $41,000. Renaissance Technologies LLC purchased a new stake in Indaptus Therapeutics in the second quarter worth about $51,000. State Street Corp purchased a new stake in Indaptus Therapeutics in the first quarter worth about $78,000. Investment House LLC lifted its stake in Indaptus Therapeutics by 272.8% in the fourth quarter. Investment House LLC now owns 95,629 shares of the company's stock worth $545,000 after acquiring an additional 69,976 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Indaptus Therapeutics by 18.7% in the first quarter. Vanguard Group Inc. now owns 242,235 shares of the company's stock worth $969,000 after acquiring an additional 38,216 shares during the period. 22.26% of the stock is owned by hedge funds and other institutional investors.
一些對衝基金最近增持或減持了Indp的股份。北方信託公司在第一季度購買了Indaptus治療公司的新股份,價值約41,000美元。文藝復興技術有限責任公司在第二季度購買了Indaptus治療公司的新股份,價值約51,000美元。道富銀行在第一季度購買了Indaptus治療公司的新股份,價值約7.8萬美元。第四季度,Investment House LLC將其在Indaptus Treeutics的持股比例提高了272.8%。Investment House LLC在此期間增持了69,976股,目前持有該公司95,629股股票,價值545,000美元。最後,先鋒集團(Vanguard Group Inc.)在第一季度增持了Indaptus Treeutics 18.7%的股份。先鋒集團(Vanguard Group Inc.)在此期間增持了38,216股,目前持有242,235股該公司股票,價值969,000美元。22.26%的股票由對衝基金和其他機構投資者持有。
Indaptus Therapeutics Stock Performance
Indaptus Treateutics股票表現
Indaptus Therapeutics (NASDAQ:INDP – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). As a group, equities research analysts expect that Indaptus Therapeutics will post -1.85 earnings per share for the current year.
Indaptus Treateutics(納斯達克:INDP-GET評級)最近一次發佈季度收益數據是在5月12日星期四。該公司公佈本季度每股收益為0.41美元,低於分析師普遍預期的0.39美元和0.02美元。作為一個集團,股票研究分析師預計Indaptus治療公司本年度的每股收益將達到1.85美元。
Indaptus Therapeutics Company Profile
Indaptus治療公司簡介
(Get Rating)
(獲取評級)
Indaptus Therapeutics, Inc, a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial.
Indaptus治療公司是一家臨牀前生物技術公司,開發各種抗癌和抗病毒免疫療法產品。它的主要臨牀腫瘤學候選藥物Decoy20對淋巴瘤、肝細胞腫瘤、結直腸腫瘤和胰腺腫瘤以及乙肝病毒和人類免疫缺陷病毒感染的單一藥物活性和/或聯合治療的持久反應,正在進行I期臨牀試驗。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Indaptus Therapeutics (INDP)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於Indaptus治療的研究報告(INDP)
- 值得關注的兩場重要的零售股大戰
- MarketBeat:回顧中的一週2012-8-8
- 什麼是WallStreetBets,他們的目標是什麼股票?
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎?
Receive News & Ratings for Indaptus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indaptus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Indaptus治療日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Indaptus治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧